Drugs / AMG 562
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03571828 | Oct 2018 → Jan 2022 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03571828 ↗ |
| Target | CD19 | “targets CD19” NCT03571828 ↗ |